1. Lasofoxifene in Postmenopausal Women with Osteoporosis
- Author
-
Cummings, Steven R, Ensrud, Kristine, Delmas, Pierre D, LaCroix, Andrea Z, Vukicevic, Slobodan, Reid, David M, Goldstein, Steven, Sriram, Usha, Lee, Andy, Thompson, John, Armstrong, Roisin A, Thompson, David D, Powles, Trevor, Zanchetta, Jose, Kendler, David, Neven, Patrick, and Eastell, Richard
- Subjects
Clinical Trials and Supportive Activities ,Aging ,Cardiovascular ,Breast Cancer ,Osteoporosis ,Clinical Research ,Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Aged ,Bone Density ,Bone Density Conservation Agents ,Breast Neoplasms ,Coronary Disease ,Female ,Fractures ,Bone ,Humans ,Middle Aged ,Osteoporosis ,Postmenopausal ,Pyrrolidines ,Receptors ,Estrogen ,Risk ,Selective Estrogen Receptor Modulators ,Spinal Fractures ,Stroke ,Tetrahydronaphthalenes ,Venous Thromboembolism ,PEARL Study Investigators ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundThe effects of lasofoxifene on the risk of fractures, breast cancer, and cardiovascular disease are uncertain.MethodsIn this randomized trial, we assigned 8556 women who were between the ages of 59 and 80 years and had a bone mineral density T score of -2.5 or less at the femoral neck or spine to receive once-daily lasofoxifene (at a dose of either 0.25 mg or 0.5 mg) or placebo for 5 years. Primary end points were vertebral fractures, estrogen receptor (ER)-positive breast cancer, and nonvertebral fractures; secondary end points included major coronary heart disease events and stroke.ResultsLasofoxifene at a dose of 0.5 mg per day, as compared with placebo, was associated with reduced risks of vertebral fracture (13.1 cases vs. 22.4 cases per 1000 person-years; hazard ratio, 0.58; 95% confidence interval [CI], 0.47 to 0.70), nonvertebral fracture (18.7 vs. 24.5 cases per 1000 person-years; hazard ratio, 0.76; 95% CI, 0.64 to 0.91), ER-positive breast cancer (0.3 vs. 1.7 cases per 1000 person-years; hazard ratio, 0.19; 95% CI, 0.07 to 0.56), coronary heart disease events (5.1 vs. 7.5 cases per 1000 person-years; hazard ratio, 0.68; 95% CI, 0.50 to 0.93), and stroke (2.5 vs. 3.9 cases per 1000 person-years; hazard ratio, 0.64; 95% CI, 0.41 to 0.99). Lasofoxifene at a dose of 0.25 mg per day, as compared with placebo, was associated with reduced risks of vertebral fracture (16.0 vs. 22.4 cases per 1000 person-years; hazard ratio, 0.69; 95% CI, 0.57 to 0.83) and stroke (2.4 vs. 3.9 cases per 1000 person-years; hazard ratio, 0.61; 95% CI, 0.39 to 0.96) Both the lower and higher doses, as compared with placebo, were associated with an increase in venous thromboembolic events (3.8 and 2.9 cases vs. 1.4 cases per 1000 person-years; hazard ratios, 2.67 [95% CI, 1.55 to 4.58] and 2.06 [95% CI, 1.17 to 3.60], respectively). Endometrial cancer occurred in three women in the placebo group, two women in the lower-dose lasofoxifene group, and two women in the higher-dose lasofoxifene group. Rates of death per 1000 person-years were 5.1 in the placebo group, 7.0 in the lower-dose lasofoxifene group, and 5.7 in the higher-dose lasofoxifene group.ConclusionsIn postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. (ClinicalTrials.gov number, NCT00141323.)
- Published
- 2010